Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson's disease: an in vivo11C-BU99008 PET study

• Published in: Brain (London, England : 1878) England : 1878), 2019-10, Vol.142 (10), p.3116-3128
• Main Authors: Wilson, Heather, Dervenoulas, George, Pagano, Gennaro, Tyacke, Robin J, Polychronis, Sotirios, Myers, Jim, Gunn, Roger N, Rabiner, Eugenii A, Nutt, David, Politis, Marios
• Format: Article
• Language: English
• Subjects: Aged; Astrocytes - metabolism; Astrocytes - pathology; Binding Sites; Brain - metabolism; Carbon Radioisotopes - metabolism; Female; Gray Matter - metabolism; Humans; Imidazoles; Imidazoline Receptors - metabolism; Imidazoline Receptors - physiology; Imidazolines - metabolism; Indoles; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease - metabolism; Parkinson Disease - pathology; Positron Emission Tomography Computed Tomography - methods; Protein Binding - physiology; Temporal Lobe - metabolism
• ISSN: 0006-8950; 1460-2156
• DOI: 10.1093/brain/awz260

Astroglia are multifunctional cells that regulate neuroinflammation and maintain homeostasis within the brain. Astroglial α-synuclein-positive cytoplasmic accumulations have been shown post-mortem in patients with Parkinson's disease and therefore astroglia may play an important role in the initiation and progression of Parkinson's disease. Imidazoline 2 binding sites are expressed on activated astroglia in the cortex, hippocampus, basal ganglia and brainstem; therefore, by measuring imidazoline 2 binding site levels we can indirectly evaluate astrogliosis in patients with Parkinson's disease. Here, we aimed to evaluate the role of astroglia activation in vivo in patients with Parkinson's disease using 11C-BU99008 PET, a novel radioligand with high specificity and selectivity for imidazoline 2 binding sites. Twenty-two patients with Parkinson's disease and 14 healthy control subjects underwent 3 T MRI and a 120-min 11C-BU99008 PET scan with volume of distribution (VT) estimated using a two-tissue compartmental model with a metabolite corrected arterial plasma input function. Parkinson's disease patients were stratified into early (n = 8) and moderate/advanced (n = 14) groups according to disease stage. In early Parkinson's disease, increased 11C-BU99008 VT uptake was observed in frontal (P = 0.022), temporal (P = 0.02), parietal (P = 0.026) and occipital (P = 0.047) cortical regions compared with healthy controls. The greatest 11C-BU99008 VT increase in patients with early Parkinson's disease was observed in the brainstem (52%; P = 0.018). In patients with moderate/advanced Parkinson's disease, loss of 11C-BU99008 VT was observed across frontal (P = 0.002), temporal (P < 0.001), parietal (P = 0.039), occipital (P = 0.024), and insula (P < 0.001) cortices; and in the subcortical regions of caudate (P < 0.001), putamen (P < 0.001) and thalamus (P < 0.001); and in the brainstem (P = 0.018) compared with healthy controls. In patients with Parkinson's disease, loss of 11C-BU99008 VT in cortical regions, striatum, thalamus and brainstem correlated with longer disease duration (P < 0.05) and higher disease burden scores, measured with Movement Disorder Society Unified Parkinson's Disease Rating Scale (P < 0.05). In the subgroup of patients with moderate/advanced Parkinson's disease, loss of 11C-BU99008 VT in the frontal (r = 0.79; P = 0.001), temporal (r = 0.74; P = 0.002) and parietal (r = 0.89; P < 0.001) cortex correlated with global cognitive impairment. This